These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 20429671)

  • 1. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.
    Younis N; Williams S; Ammori B; Soran H
    Expert Opin Pharmacother; 2010 Jun; 11(9):1459-66. PubMed ID: 20429671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis.
    Zhang C; Sun A; Zhang P; Wu C; Zhang S; Fu M; Wang K; Zou Y; Ge J
    Diabetes Res Clin Pract; 2010 Feb; 87(2):211-8. PubMed ID: 19853947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.
    Allemann S; Diem P; Egger M; Christ ER; Stettler C
    Curr Med Res Opin; 2006 Mar; 22(3):617-23. PubMed ID: 16574044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis.
    Berger JS; Brown DL; Becker RC
    Am J Med; 2008 Jan; 121(1):43-9. PubMed ID: 18187072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
    Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
    J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
    Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
    Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.
    Prescrire Int; 2010 Nov; 19(110):258-61. PubMed ID: 21284360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Howard G
    Am J Cardiol; 2006 Sep; 98(6):746-50. PubMed ID: 16950176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Acetylsalicylic acid for the primary prevention of cardiovascular disease in diabetic patients].
    de Lange DW; Fiets WE; Banga JD
    Ned Tijdschr Geneeskd; 2004 Jul; 148(30):1481-5. PubMed ID: 15481570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of aspirin in the primary prevention of cardiovascular disease].
    Rodondi N; Cornuz J
    Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on aspirin in the primary prevention of cardiovascular disease.
    Eidelman RS; Hebert PR; Weisman SM; Hennekens CH
    Arch Intern Med; 2003 Sep; 163(17):2006-10. PubMed ID: 14504112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Acetylsalicylic acid in patients with diabetes mellitus: can be used for secondary but not primary prevention of cardiovascular events].
    Klomp CM; ten Cate H; Stehouwer CD; Schaper NC
    Ned Tijdschr Geneeskd; 2009; 153():A109. PubMed ID: 19785798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis.
    Burger W; Chemnitius JM; Kneissl GD; Rücker G
    J Intern Med; 2005 May; 257(5):399-414. PubMed ID: 15836656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
    Sirois C; Poirier P; Moisan J; Grégoire JP
    Int J Cardiol; 2008 Sep; 129(2):172-9. PubMed ID: 18495263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.